VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.

[1]  B. Clotet,et al.  Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform—Analysis of Production and Immunogenicity , 2023, International journal of molecular sciences.

[2]  B. Clotet,et al.  An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses , 2023, npj Vaccines.

[3]  T. Morrison,et al.  The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate , 2023, Journal of virology.

[4]  L. Lei,et al.  Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice , 2022, Frontiers in Immunology.

[5]  M. Barbagallo,et al.  Rate of Hospitalizations and Mortality of Respiratory Syncytial Virus Infection Compared to Influenza in Older People: A Systematic Review and Meta-Analysis , 2022, Vaccines.

[6]  H. Su,et al.  Profiling of hMPV F-specific antibodies isolated from human memory B cells , 2022, Nature Communications.

[7]  L. Smitherman,et al.  Socioeconomic Impact of RSV Hospitalization , 2021, Infectious Diseases and Therapy.

[8]  G. Ahmadian,et al.  Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers , 2021, Journal of Nanobiotechnology.

[9]  M. Lucero,et al.  Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study , 2020, The Lancet. Global health.

[10]  L. Anderson,et al.  Two RSV Platforms for G, F, or G+F Proteins VLPs , 2020, Viruses.

[11]  H. Su,et al.  Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes , 2019, mAbs.

[12]  J. Mascola,et al.  A proof of concept for structure-based vaccine design targeting RSV in humans , 2019, Science.

[13]  David Baker,et al.  Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus , 2019, Cell.

[14]  T. Morrison,et al.  Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein , 2019, Vaccines.

[15]  Amy S. Espeseth,et al.  Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein , 2016, PloS one.

[16]  Dong Soo Yun,et al.  HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies , 2016, Immunity.

[17]  Cinque S. Soto,et al.  Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine , 2016, Nature Structural &Molecular Biology.

[18]  R. Wyatt,et al.  High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. , 2016, Cell reports.

[19]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[20]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[21]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[22]  R. Lamb,et al.  Structure of the Human Metapneumovirus Fusion Protein with Neutralizing Antibody Identifies a Pneumovirus Antigenic Site , 2012, Nature Structural &Molecular Biology.

[23]  P. Kwong,et al.  Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes , 2011, Journal of Virology.

[24]  C. Mandl,et al.  Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers , 2011, Proceedings of the National Academy of Sciences.

[25]  Andreas Radbruch,et al.  Generation of stable monoclonal antibody-producing BCR+ human memory B cells by genetic programming , 2009, Nature Medicine.

[26]  D. Bracewell,et al.  Exploiting the intracellular compartmentalization characteristics of the S. cerevisiae host cell for enhancing primary purification of lipid‐envelope virus‐like particles , 2009, Biotechnology progress.

[27]  Manmohan J. Singh,et al.  Endotoxin limits in formulations for preclinical research. , 2008, Journal of pharmaceutical sciences.

[28]  N. Pujar,et al.  Study of Detergent‐Mediated Liberation of Hepatitis B Virus‐like Particles from S. cerevisiae Homogenate: Identifying a Framework for the Design of Future‐Generation Lipoprotein Vaccine Processes , 2008, Biotechnology progress.

[29]  R. Sarisky,et al.  The cytoplasmic domain of the F protein of Human respiratory syncytial virus is not required for cell fusion. , 2006, The Journal of general virology.

[30]  W. P. Glezen,et al.  Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. , 2003, Vaccine.

[31]  C. Paidas,et al.  GENETIC CONTRIBUTION TO THE SEPTIC RESPONSE IN A MOUSE MODEL , 2002, Shock.

[32]  E. Walsh,et al.  Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. , 1998, The Journal of infectious diseases.

[33]  D. Pfarr,et al.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. , 1997, The Journal of infectious diseases.

[34]  C. Hsieh,et al.  T cell genetic background determines default T helper phenotype development in vitro , 1995, The Journal of experimental medicine.

[35]  K. Coelingh,et al.  Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function , 1989, Journal of virology.

[36]  S. Doyle,et al.  Fatty acid acylation of the fusion glycoprotein of human respiratory syncytial virus. , 1989, The Journal of biological chemistry.

[37]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.

[38]  J. Wiśniewski.  Filter-Aided Sample Preparation: The Versatile and Efficient Method for Proteomic Analysis. , 2017, Methods in enzymology.

[39]  Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. , 1998, Pediatrics.